Drugs / PVT201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06798454 | Oct 2024 → Apr 2025 | primary biliary cholangitis | Parvus Therapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-11-12 | Parvus Therapeutics, Inc. | Results Parvus Therapeutics Reports Positive Phase 1 Results for Lead Autoimmune Treg Therapy, PVT201 parvustx.com ↗
PVT201 was safe and well tolerated across all dose levels, with no serious adverse events and no clinically meaningful changes in vital signs, ECGs, or laboratory parameters. |
| 2024-07-29 | Parvus Therapeutics, Inc. | Regulatory Parvus Therapeutics announces that PVT201 has received Orphan Drug Designation parvustx.com ↗
Parvus Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to PVT201 for the treatment of Primary Biliary Cholangitis (PBC) and PVT201 has obtained Australian Human Research Ethics Committee (HREC) approval to initiate a first-in-human Phase I clinical trial. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-12 | Parvus Therapeutics, Inc. | Parvus Therapeutics Reports Positive Phase 1 Results for Lead Autoimmune Treg Therapy, PVT201 parvustx.com ↗ |
| 2024-10-15 | Parvus Therapeutics, Inc. | Parvus Announces First Human Subject Dosed in a Clinical Trial with PVT201, a First-in-Class Off-the-Shelf Regulatory T-Cell (Treg) Inducing pMHC Nanomedicine Therapy parvustx.com ↗ |
| 2024-07-29 | Parvus Therapeutics, Inc. | Parvus Therapeutics announces that PVT201 has received Orphan Drug Designation parvustx.com ↗ |
| 2021-11-29 | Parvus Therapeutics, Inc. | Parvus Therapeutics Announces Development and Manufacturing Agreement with Resilience to Advance Novel Autoimmune Drug Candidate PVT201 parvustx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PVT201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06798454 ↗ |
| Route | Intravenous | “PVT201 will be administered intravenously.” NCT06798454 ↗ |